Royalty Pharma Plc Stock Fundamentals
| RPRX Stock | USD 26.60 0.31 1.18% |
Royalty Pharma Plc fundamentals help investors to digest information that contributes to Royalty Pharma's financial success or failures. It also enables traders to predict the movement of Royalty Stock. The fundamental analysis module provides a way to measure Royalty Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Royalty Pharma stock.
At this time, Royalty Pharma's Interest Expense is fairly stable compared to the past year. Total Revenue is likely to rise to about 2.5 B in 2024, whereas Gross Profit is likely to drop slightly above 1.4 B in 2024. Royalty | Select Account or Indicator |
Royalty Pharma Plc Company Return On Equity Analysis
Royalty Pharma's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Royalty Pharma Return On Equity | 0.17 |
Most of Royalty Pharma's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Royalty Pharma Plc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Royalty Return On Equity Historical Pattern
Today, most investors in Royalty Pharma Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Royalty Pharma's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's return on equity growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Royalty Pharma return on equity as a starting point in their analysis.
Royalty Pharma Return On Equity |
| Timeline |
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Royalty Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, Royalty Pharma Plc has a Return On Equity of 0.1728. This is 100.72% lower than that of the Pharmaceuticals sector and 100.47% lower than that of the Health Care industry. The return on equity for all United States stocks is 155.74% lower than that of the firm.
Royalty Pharma Plc Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Royalty Pharma's current stock value. Our valuation model uses many indicators to compare Royalty Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Royalty Pharma competition to find correlations between indicators driving Royalty Pharma's intrinsic value. More Info.Royalty Pharma Plc is currently regarded as top stock in return on equity category among its peers. It also is currently regarded as top stock in return on asset category among its peers reporting about 0.33 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Royalty Pharma Plc is roughly 3.04 . At this time, Royalty Pharma's Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Royalty Pharma's earnings, one of the primary drivers of an investment's value.Royalty Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Royalty Pharma's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Royalty Pharma could also be used in its relative valuation, which is a method of valuing Royalty Pharma by comparing valuation metrics of similar companies.Royalty Pharma is currently under evaluation in return on equity category among its peers.
Royalty Pharma ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Royalty Pharma's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Royalty Pharma's managers, analysts, and investors.Environmental | Governance | Social |
Royalty Fundamentals
| Return On Equity | 0.17 | ||||
| Return On Asset | 0.0569 | ||||
| Profit Margin | 0.51 % | ||||
| Operating Margin | 1.30 % | ||||
| Current Valuation | 17.52 B | ||||
| Shares Outstanding | 444.3 M | ||||
| Shares Owned By Insiders | 13.16 % | ||||
| Shares Owned By Institutions | 72.77 % | ||||
| Number Of Shares Shorted | 14.67 M | ||||
| Price To Earning | 37.70 X | ||||
| Price To Book | 1.70 X | ||||
| Price To Sales | 6.92 X | ||||
| Revenue | 2.35 B | ||||
| Gross Profit | 1.33 B | ||||
| EBITDA | 1.89 B | ||||
| Net Income | 1.13 B | ||||
| Cash And Equivalents | 1.47 B | ||||
| Cash Per Share | 3.34 X | ||||
| Total Debt | 6.14 B | ||||
| Debt To Equity | 0.68 % | ||||
| Current Ratio | 2.07 X | ||||
| Book Value Per Share | 15.40 X | ||||
| Cash Flow From Operations | 2.99 B | ||||
| Short Ratio | 6.10 X | ||||
| Earnings Per Share | 2.54 X | ||||
| Price To Earnings To Growth | 5.71 X | ||||
| Target Price | 41.53 | ||||
| Beta | 0.47 | ||||
| Market Capitalization | 15.67 B | ||||
| Total Asset | 16.38 B | ||||
| Retained Earnings | 2.52 B | ||||
| Working Capital | 1.11 B | ||||
| Current Asset | 10.66 M | ||||
| Current Liabilities | 2.31 M | ||||
| Annual Yield | 0.03 % | ||||
| Net Asset | 16.38 B | ||||
| Last Dividend Paid | 0.83 |
About Royalty Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Royalty Pharma Plc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Royalty Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Royalty Pharma Plc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 27.9 M | 24.8 M | |
| Total Revenue | 2.4 B | 2.5 B | |
| Cost Of Revenue | 560.7 M | 588.7 M | |
| Sales General And Administrative To Revenue | 0.11 | 0.06 | |
| Research And Ddevelopement To Revenue | 0.02 | 0.02 | |
| Capex To Revenue | 1.05 | 0.83 | |
| Revenue Per Share | 5.26 | 3.72 | |
| Ebit Per Revenue | 0.63 | 0.54 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Royalty Stock Analysis
When running Royalty Pharma's price analysis, check to measure Royalty Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Royalty Pharma is operating at the current time. Most of Royalty Pharma's value examination focuses on studying past and present price action to predict the probability of Royalty Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Royalty Pharma's price. Additionally, you may evaluate how the addition of Royalty Pharma to your portfolios can decrease your overall portfolio volatility.